Oculis Holding AG (NASDAQ:OCS – Get Free Report)’s share price traded up 3.8% on Tuesday . The company traded as high as $15.17 and last traded at $15.17. 5,473 shares changed hands during trading, a decline of 85% from the average session volume of 36,819 shares. The stock had previously closed at $14.62.
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Oculis in a research report on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $29.20.
Oculis Trading Down 0.7 %
Oculis (NASDAQ:OCS – Get Free Report) last posted its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. The company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. On average, research analysts expect that Oculis Holding AG will post -2.09 earnings per share for the current year.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Read More
- Five stocks we like better than Oculis
- Top Biotech Stocks: Exploring Innovation Opportunities
- Is Biotech’s Bull Run Over? Examining Election Impacts
- Comparing and Trading High PE Ratio Stocks
- 3 Stocks Generating a Ridiculous Amount of Cash
- What Are Dividend Achievers? An Introduction
- Dividend Growth Meets Chips: Top 3 Semiconductor Stocks to Watch
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
